Pharma analysts have different opinions on how much branded drugmakers will feel the heat from biosimilars--and when they'll feel it. But according to one Citi analyst, they're all underestimating the impact on AbbVie's top dog.
Good news for Teva when it comes to Mylan's generic version of AstraZeneca's Nexium: It won't be around for a little while.
SINGAPORE-- Pakistan's pharmaceutical industry reportedly has decided to step aside and cease opposition to a government plan to force down the price of certain drugs marketed in the country as of July 1, 2016.
SINGPAPORE-- Merck has confirmed it will move to let Simcere Pharmaceuticals run a high-profile China joint venture aimed at branded generic drugs announced in 2011 and focus instead on its mature products in the local market.
The U.S. FDA is hiring new inspectors in India to tackle the high rate of marketing applications made by local firms, an agency official said.
SINGAPORE-- India's government is getting into the generic drug business. The state reportedly will launch its own brand, "Jan Aushadhi," on July 1, planning to sell up to 504 drugs on its "essential" list in direct competition with commercial drugmakers.
Ranbaxy Laboratories may soon be selling its generic minocycline antibacterial drug to Torrent Pharmaceuticals as a condition for U.S. approval for its merger with Sun Pharmaceuticals.
It's no secret that branded drugmakers often rely on price hikes to keep U.S. sales growth coming, especially on older meds whose patents are close to the ends of their lives. But according to new data, prices spiked more than 10% last year--a trend that may fuel the payer backlash that's been steadily mounting.
SINGAPORE-- More than two years in the making, Pakistan's proposed new drug-pricing policy still hasn't won over drugmakers. The country's health ministry proffered a draft that would peg prices to those in India and Bangladesh, with generic prices at 30% less, on average, than the brand price in those neighboring countries.
SINGAPORE-- Undeterred by its loss of a new patent bid for its Sovaldi (sofosbuvir) hepatitis C drug in India, Gilead Sciences put together package deals with 8 of the country's generics makers to add an experimental drug to a deal for low-cost copies in 91 poor countries around the world. Meanwhile, Gilead said Sovaldi won marketing approval this month in India and it's off and running in that country.